
Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target
Aurinia Pharmaceuticals (AUPH) Analyst Ratings
Bulls say
Aurinia Pharmaceuticals is attractive because LUPKYNIS continues to deliver durable commercial growth, with Q3/26 net product sales of $79.4MM up 12% y/y and 2026 product sales guidance raised to $310–315MM, while total revenue guidance increased to $325–330MM. Its fundamentals are further supported by strong profitability and liquidity, as Q3/26 net income was about $31.7MM, cash and investments reached roughly $486.9MM, and operating cash flow remained solid at $46.4MM. Beyond the base business, the under-penetrated lupus nephritis market, the ~41% renal response seen in Phase III, and aritinercept progressing across four indications create additional long-term growth optionality, while favorable legal developments around exclusivity improve the durability of earnings power.
Bears say
Aurinia Pharmaceuticals is viewed negatively because its valuation is heavily dependent on LUPKYNIS, while the pipeline is thin with aritinercept still in early clinical development and no disclosed near-term catalyst strong enough to offset core product risk. Patent litigation remains a major overhang, with seven to eight generic filers challenging exclusivity and a proposed bench trial in early 2028, creating a meaningful chance of generic erosion as soon as mid-2028 or even 2027 in downside cases. Adoption and competition risks further pressure the outlook, as slower-than-expected penetration and new lupus nephritis therapies from better-resourced large pharma could erode sales and leave little value in the downside scenario beyond LUPKYNIS.
This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Aurinia Pharmaceuticals (AUPH) Analyst Forecast & Price Prediction
Start investing in Aurinia Pharmaceuticals (AUPH)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Aurinia Pharmaceuticals (AUPH) Forecast
Aurinia Pharmaceuticals (AUPH) Analyst Forecast & Price Prediction
Start investing in Aurinia Pharmaceuticals (AUPH)
Order type
Buy in
Order amount
Est. shares
0 shares